Antipsychotics for children and young adults: a comparative effectiveness review

Pediatrics
Jennifer C SeidaNormand Carrey

Abstract

Despite increasing on-label and off-label use of antipsychotics, prescribing antipsychotics to children remains controversial due to uncertainty of their relative benefits and safety. We systematically reviewed the effectiveness and safety of first- (FGA) and second-generation antipsychotics (SGA) for patients aged ≤24 years with psychiatric and behavioral conditions. We searched 10 databases from January 1987 to February 2011, gray literature, trial registries, and reference lists. Two reviewers independently selected studies, assessed methodologic quality, and graded the evidence. One reviewer extracted, and a second verified, data. We summarized findings qualitatively and conducted meta-analyses when appropriate. Sixty-four trials and 17 cohort studies were included. Most trials had a high risk of bias; cohort studies had moderate quality. All comparisons of FGAs versus SGAs, FGAs versus FGAs, and FGAs versus placebo had low or insufficient strength of evidence. There was moderate strength of evidence for the following comparisons. Olanzapine caused more dyslipidemia and weight gain, but fewer prolactin-related events, than risperidone. Olanzapine caused more weight gain than quetiapine. Compared with placebo, SGAs improved ...Continue Reading

Citations

May 9, 2013·Social Psychiatry and Psychiatric Epidemiology·Yuan-Chang HsuPesus Chou
Jan 16, 2013·The Journal of Behavioral Health Services & Research·Leslie MillerSusan dosReis
Aug 7, 2013·Paediatric Drugs·Edwin A Lomotan, Denise Dougherty
Nov 29, 2012·Journal of Medical Case Reports·Luigi MazzoneStefano Vicari
Nov 15, 2013·Systematic Reviews·Nadera AhmadzaiPaul G Shekelle
Mar 13, 2014·Harvard Review of Psychiatry·Carol CurtinLinda G Bandini
May 3, 2014·SpringerPlus·Inmaculada Palanca-MarescaChristoph U Correll
Oct 10, 2013·BMC Psychiatry·David LintonAlasdair M Barr
May 15, 2013·Therapeutic Drug Monitoring·Danielle S FisherRobert J Flanagan
Jan 21, 2015·Scandinavian Journal of Clinical and Laboratory Investigation·Jari E KaikkonenOlli T Raitakari
Jan 28, 2016·Journal of Clinical Pharmacy and Therapeutics·N El-SaifiH Tuffaha
Sep 10, 2013·Child and Adolescent Psychiatric Clinics of North America·Harvey N Kranzler, Sarah D Cohen
Jan 20, 2016·Journal of Child and Adolescent Psychopharmacology·Andrea MannKate Keenan
Oct 9, 2012·Child and Adolescent Psychiatric Clinics of North America·Georgina GarciaJoseph Gonzalez-Heydrich
Dec 26, 2015·Journal of the American Academy of Child and Adolescent Psychiatry·Molly FinnertyMark Olfson
Aug 30, 2014·Academic Pediatrics·Edith KealeyMolly Finnerty
Jan 5, 2013·Pharmacology, Biochemistry, and Behavior·Christina A Wilson, Alvin V Terry
Feb 18, 2014·ISRN Obesity·Andrea Lynn MurphyJean Hughes
Dec 3, 2014·Journal of the American Academy of Child and Adolescent Psychiatry·Celso ArangoMara Parellada
Apr 20, 2016·Journal of Child and Adolescent Psychopharmacology·Zainab Al-DhaherMaren Carbon
Sep 9, 2016·Journal of Child and Adolescent Psychopharmacology·Paramala J SantoshJatinder Singh
Sep 15, 2016·European Child & Adolescent Psychiatry·Carsten SchröderOliver Riedel
Nov 24, 2016·International Journal of Molecular Sciences·Michael De SantisChao Deng
Jan 24, 2014·Journal of Psychopharmacology·Jessica MemarziaGiovanni Giaroli
Aug 10, 2017·The Cochrane Database of Systematic Reviews·Jik H LoyKarolina Stasiak
Jul 27, 2018·Journal of Child and Adolescent Psychopharmacology·Przemysław M WaszakAlicja Kubanek
Nov 7, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Danielle Stutzman, Julie Dopheide
Nov 22, 2013·Current Psychiatry Reports·Robert B PenfoldGregory E Simon
Jul 25, 2019·Psychiatric Services : a Journal of the American Psychiatric Association·Serene OlinSarah Hudson Scholle
Apr 21, 2020·Epidemiology and Psychiatric Sciences·Florentia KaguelidouGianluca Trifirò
Mar 5, 2016·Current Psychiatry Reports·Beau CarubiaB Harrison Levine
Feb 18, 2015·Paediatric Drugs·Gabriele MasiSimone Pisano
Jul 15, 2016·Journal of Psychopharmacology·Aung Aung Kywe MoeDarryl W Eyles
Nov 24, 2017·Pharmacy : Journal of Pharmacy, Education and Practice·Minji SohnMohamed Bazzi
Oct 23, 2020·Journal of the American Academy of Child and Adolescent Psychiatry·Greta A BushnellMark Olfson
Apr 2, 2021·Journal of Autism and Developmental Disorders·Haley J KillianMeredith L Dreyer Gillette
Mar 30, 2021·Frontiers in Psychiatry·Mark R Libowitz, Erika L Nurmi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Related Papers

Ambulatory Pediatrics : the Official Journal of the Ambulatory Pediatric Association
William O CooperWayne A Ray
The New England Journal of Medicine
Robert Steinbrook
© 2022 Meta ULC. All rights reserved